# Britannia Pharmaceuticals Ltd.: Observational study closed enrollment, 312 enrolled (Advanced Parkinson Disease)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Britannia Pharmaceuticals Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease |
| NCT ID | NCT05043103 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Advanced Parkinson Disease |
| Intervention types | combination product |
| Target enrollment | 312 |
| Site countries | Austria, Belgium, Bulgaria, Croatia, Czechia, Denmark, Germany, Hungary, Ireland, Netherlands, Romania, Slovenia |
| Posted | 2021-09-14 |
| Planned start | 2021-07-06 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-06 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 312 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05043103). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.